Business
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid tumors Presentation at Nova Southeastern University on September 12, 2025, in Fort Lauderdale, Florida MIRAMAR, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on disco
About this update from Hcw Biologics Inc.
[{"type":"image","alt":"HCW Biologics Inc.","displaySize":"","headline":null,"caption":"HCW Biologics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/41c465fea041fccd686f09c17f724fb7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8op9ybYTjyQdFXiaAcCiSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/41c465fea041fccd686f09c17f724fb7","width":300,"height":150}},"lazy":false},{"type":"text","content":"Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid tumors","length":219,"tagName":"p"},{"type":"text","content":"Presentation at Nova Southeastern University on September 12, 2025, in Fort Lauderdale, Florida","length":101,"tagName":"p"},{"type":"text","content":"MIRAMAR, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today that its scientists have successfully developed second-generation, pembrolizumab-based immunotherapeutics against solid tumors, particularly for pancreatic and ovarian cancer, using its novel proprietary TRBC product discovery and development platform technology.","length":606,"tagName":"p"},{"type":"text","content":"Since their introduction to the treatment of cancer in 2011, immune checkpoint inhibitors (“ICIs”) have been hailed as a breakthrough cancer therapy. Immune checkpoint proteins are expressed on the surface of T cells as the acting regulators for inhibiting the over-activation of T cells. By using ICIs, the immune response of T cells can be largely activated to re-establish the immune effects of anti-tumor exhausted T cells. However, there is vast evidence in preclinical and clinical studies suggesting that the lack of immune-cell costimulatory activities on ICIs diminishes their anti-tumor efficacy.","length":606,"tagName":"p"},{"type":"text","content":"Dr. Hing C. Wong, Founder and CEO of the Company, stated, “Immune checkpoint inhibitors ...